Core Viewpoint - Yong'an Pharmaceutical announced the absorption merger of its affiliated company Huanggang Daily Chemical by its wholly-owned subsidiary Hubei Tian'an Daily Chemical, resulting in a change of investment targets and related party transactions [1] Group 1: Merger Details - The merger involves Huanggang Daily Chemical being absorbed by Hubei Tian'an Daily Chemical, with Tian'an Daily Chemical as the surviving entity and Huanggang Daily Chemical being dissolved [1] - The merger will not involve cash payments; shareholders of Huanggang Daily Chemical will exchange their shares for equity in Tian'an Daily Chemical on a pro-rata basis [1] - After the merger, the original investment of 30 million yuan in Huanggang Daily Chemical will convert to a direct investment in Tian'an Daily Chemical, maintaining a shareholding ratio of 6.5217% [1] Group 2: Related Party Transactions - The transaction constitutes a related party transaction as the controlling shareholder and actual controller, Mr. Chen Yong, is also the actual controller of Huanggang Daily Chemical and Tian'an Daily Chemical [1] - The merger does not require submission for shareholder meeting approval [1]

Group 1 - The core point of the article is that Yong'an Pharmaceutical announced a temporary board meeting to discuss a merger involving its subsidiary, which will lead to changes in investment targets and related transactions [1] - For the first half of 2025, Yong'an Pharmaceutical's revenue composition is as follows: pharmaceutical manufacturing accounts for 64.14%, health food accounts for 24.67%, chemical manufacturing accounts for 10.88%, and other businesses account for 0.32% [1] - As of the report, Yong'an Pharmaceutical has a market capitalization of 5.3 billion yuan [1] Group 2 - Prior to the arrest of the chairman of Peking University Pharmaceutical, police had investigated the group's factory premises, indicating potential issues within the company [1] - Internal sources suggest that the group's assets have been disposed of by the chairman, with significant amounts of funds unaccounted for [1]

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) is consolidating resources and improving efficiency by merging its subsidiary Huanggang Yong'an Daily Chemical Co., Ltd. into its wholly-owned subsidiary Hubei Tian'an Daily Chemical Co., Ltd. [1] Group 1: Merger Details - The merger will result in Tian'an Daily Chemical being the surviving entity, while Huanggang Daily Chemical will be dissolved [1] - The merger does not involve any cash payments; shareholders of Huanggang Daily Chemical will exchange their shares for equity in Tian'an Daily Chemical on a pro-rata basis [1] - After the merger, all assets, liabilities, and equity of Huanggang Daily Chemical will be legally inherited by Tian'an Daily Chemical [1] Group 2: Investment Implications - The company's previous investment of 30 million yuan in Huanggang Daily Chemical will be converted into a direct investment in Tian'an Daily Chemical [1] - The shareholding ratio will remain unchanged, with the company directly holding 6.5217% of Tian'an Daily Chemical's equity post-merger [1]

证券代码：002365 证券简称：永安药业 公告编号：2025-66 潜江永安药业股份有限公司 关于参股公司黄冈日化拟被其全资子公司吸收合并 导致投资标的发生变更暨关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关联交易概述 为整合资源、提高效率、降低成本，潜江永安药业股份有限公司（以下简称 "公司"）参股公司黄冈永安日用化工有限公司（以下简称"黄冈日化"）拟被 其全资子公司湖北天安日用化工有限公司（以下简称"天安日化"）吸收合并， 以天安日化为合并存续方，黄冈日化为被合并方。本次吸收合并不涉及现金收付， 黄冈日化各股东将以其原持有的黄冈日化股权所对应的权益，通过换股方式等比 例转为直接持有天安日化的股权。合并完成后，黄冈日化将予以注销，其全部资 产、负债、权益等由天安日化依法承继。公司原对黄冈日化 3,000 万元投资将转 变为公司对天安日化的投资，持股比例将由间接持有天安日化 6.5217%的股权转 为直接持有天安日化 6.5217%的股权。 公司控股股东及实际控制人陈勇先生系黄冈永安药业股份有限公司（以下简 称"黄冈永安"）、黄冈日化 ...

表决结果：以同意 5 票，反对 0 票，弃权 0 票，回避表决 2 票。关联董 事陈勇先生、陈子笛先生回避了对本项议案的表决。 董事会同意参股公司黄冈日化被其全资子公司吸收合并，合并完成后，黄冈 日化将予以注销，其全部资产、负债、权益由天安日化依法承继。本次吸收合并 不涉及现金收付，黄冈日化各股东将以其原持有的黄冈日化股权所对应的权益， 通过换股方式等比例转为直接持有天安日化的股权。公司原对黄冈日化 3,000 万元投资将转变为公司对天安日化的投资，持股比例将由间接持有天安日化 6.5217%的股权转为直接持有天安日化 6.5217%的股权。 第七届董事会第十一次临时会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司（以下简称"公司"）第七届董事会第十一次临 时会议的会议通知于 2025 年 11 月 7 日以书面、电话、传真、电子邮件等形式送 达公司全体董事，会议于 2025 年 11 月 11 日在公司会议室以通讯方式召开，本 次会议应参与审议表决董事 7 人，实际参与审议表决董事 7 人。本次会议由公 司董事长陈勇先生 ...

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) announced the absorption merger of its affiliate Huanggang Yong'an Daily Chemical Co., Ltd. by its wholly-owned subsidiary Hubei Tian'an Daily Chemical Co., Ltd. This merger aims to integrate resources, improve efficiency, and reduce costs [1] Group 1: Merger Details - The merger will not involve any cash payments, and shareholders of Huanggang Daily Chemical will exchange their shares for direct equity in Tian'an Daily Chemical [1] - After the merger, Huanggang Daily Chemical will be dissolved, and all its assets, liabilities, and equity will be legally inherited by Tian'an Daily Chemical [1] - The company's previous investment of 30 million yuan in Huanggang Daily Chemical will convert into a direct investment in Tian'an Daily Chemical, maintaining a shareholding ratio of 6.5217% [1] Group 2: Strategic Implications - The merger is expected to optimize the management structure of the affiliate, reduce management costs, and enhance decision-making efficiency [1] - This move aligns with the overall development strategy of the company, aiming to fully leverage the economic benefits of asset integration [1]

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) announced a merger where its subsidiary Huanggang Yong'an Daily Chemical Co., Ltd. will be absorbed by its wholly-owned subsidiary Hubei Tianan Daily Chemical Co., Ltd. This merger aims to optimize management structure, reduce costs, and enhance decision-making efficiency, aligning with the company's overall development strategy [1]. Summary by Relevant Sections - **Merger Details** - Huanggang Yong'an Daily Chemical will be merged into Hubei Tianan Daily Chemical, with Tianan Daily Chemical as the surviving entity and Huanggang Daily Chemical being dissolved [1]. - The merger will not involve cash payments; shareholders of Huanggang Daily Chemical will exchange their shares for direct equity in Tianan Daily Chemical [1]. - After the merger, the company's investment of 30 million yuan in Huanggang Daily Chemical will convert to a direct investment in Tianan Daily Chemical, maintaining a shareholding ratio of 6.5217% [1]. - **Strategic Benefits** - The merger is expected to optimize the management structure of the subsidiary, reduce management costs, and improve decision-making efficiency [1]. - The consolidation is anticipated to leverage economic benefits from asset integration, which is in line with the company's strategic development goals [1].

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) is consolidating resources and improving efficiency by merging its subsidiary Huanggang Yong'an Daily Chemical Co., Ltd. into its wholly-owned subsidiary Hubei Tian'an Daily Chemical Co., Ltd. [1] Group 1 - The merger will not involve any cash payments, and shareholders of Huanggang Daily Chemical will exchange their equity for direct ownership in Tian'an Daily Chemical through a share swap [1] - After the merger, Huanggang Daily Chemical will be dissolved, and all its assets, liabilities, and equity will be legally inherited by Tian'an Daily Chemical [1] - The company's previous investment of 30 million yuan in Huanggang Daily Chemical will convert into a direct investment in Tian'an Daily Chemical, maintaining a shareholding ratio of 6.5217% [1]

Group 1 - The core viewpoint of the news is that Yong'an Pharmaceutical has shown significant stock performance, with a year-to-date increase of 125.80% and a recent price of 17.82 CNY per share, reflecting strong market interest and trading activity [1][2] - As of October 31, the number of shareholders for Yong'an Pharmaceutical is 57,100, a decrease of 4.28% from the previous period, while the average circulating shares per person increased by 4.48% to 4,296 shares [2] - The company operates primarily in the pharmaceutical sector, focusing on the research, production, and sales of taurine products, which account for 64.14% of its main business revenue [1][2] Group 2 - For the period from January to September 2025, Yong'an Pharmaceutical reported a revenue of 577 million CNY, a year-on-year decrease of 6.72%, and a net profit attributable to the parent company of 25.5 million CNY, down 58.78% year-on-year [2] - The company has distributed a total of 401 million CNY in dividends since its A-share listing, with 87.7 million CNY distributed over the past three years [3]

Group 1 - Semiconductor Manufacturing International Corporation (SMIC) plans to acquire 47% equity in SMIC North, with due diligence and evaluation processes still ongoing [1][2] - Zhuhai Gree Supply Chain intends to convert a debt of 200 million yuan into equity to increase capital for Shenzhen Haoneng Technology, changing its status from a wholly-owned subsidiary to a controlling subsidiary [3] - China Huadian Corporation is set to invest 12.043 billion yuan in a combined heat and power generation project integrated with renewable energy in Heilongjiang [4] Group 2 - Yong'an Pharmaceutical announces that some directors and senior management plan to reduce their holdings by up to 0.0799% of the total shares [5] - Lihua Co. reports a 11.44% year-on-year increase in chicken sales revenue for October, totaling 1.461 billion yuan [6] - Degu Technology intends to terminate the acquisition of 100% equity in Haowei Technology due to difficulties in meeting the demands of all parties involved [7] Group 3 - Guocheng Mining plans to pay 3.168 billion yuan in cash to acquire 60% equity in Guocheng Industrial [8] - Yingtang Intelligent Control intends to acquire 100% equity in Guanglong Integration and 80% equity in Aojian Microelectronics, with stock resuming trading on November 10 [9] - Shanshan Holdings announces that its actual controller and major shareholder have divorced, resulting in a change in control [10] Group 4 - Nutaige plans to invest 100 million yuan to establish a wholly-owned subsidiary focused on robotics and related components [11] - Chengxing Co. reports that its Jiangyin factory is currently under temporary shutdown for rectification due to a raw material leak [12] - Xindong Holdings announces that its shareholder Hainan Zhuhua plans to reduce its stake by up to 3% [13] Group 5 - Yonghui Supermarket's vice president has completed a share reduction of 0.0012% [14] - Xi'an Tourism plans to issue A-shares to raise no more than 300 million yuan for working capital and bank loan repayment [15] - Xiaogoods City has successfully acquired land use rights for a commercial site in Yiwu for 3.223 billion yuan [16][17] Group 6 - Tongda Chuangzhi announces a cash dividend of 6 yuan per 10 shares for the 2025 interim period [18] - Shen Nan Electric A received a government subsidy of 8.0518 million yuan, accounting for 36.75% of its last fiscal year's net profit [19] - Founder Technology's subsidiary plans to invest 1.364 billion yuan in an AI expansion project in Chongqing [20] Group 7 - Hezhong China reports significant stock trading fluctuations, indicating a "hot potato" effect [21] - Hengrui Medicine's subsidiary has received approval for clinical trials of SHR-4610 injection for late-stage solid tumors [22] - Sihua Holdings announces the termination of a restructuring investment agreement and continues to seek potential investors [23] Group 8 - Yingwei Technology's subsidiary has won a 27.78% share of a project from China Mobile [24] - Dabeinong reports a 45.20% year-on-year increase in pig sales for October, totaling 5.79 billion yuan [25] - Meihua Biotech's major shareholder has been sentenced for market manipulation, but it does not affect the company's operations [26] Group 9 - Zhongyi Da plans to terminate the issuance of A-shares to specific investors [27] - Zhongji Oil and Gas has received a notice of investigation from the China Securities Regulatory Commission regarding trading violations [28] - China International Trade Corporation announces the resignation of its chairman due to work reasons [29] Group 10 - GAC Group reports a decline in October vehicle sales by 8.10% [30] - Dameng Data has invested 100 million yuan to establish an investment fund focused on the database industry [31] - Zhengbang Technology reports a 78.08% year-on-year increase in pig sales revenue for the first ten months [32] Group 11 - Shanghai Xiba has announced that its directors are under investigation for suspected short-term trading [33] - Changgao Electric New has won a bid for a project from the State Grid worth 246 million yuan [34] - Jianghuai Automobile reports a 5.49% increase in October sales [35] Group 12 - Xintian Green Energy reports a 20.97% year-on-year decrease in power generation for October [36] - Luokang Pharmaceutical's products have been selected in the national centralized procurement [37] - Zhongyuan Home intends to invest 16 million USD in a self-built production base in Vietnam [38] Group 13 - Changcheng Technology has terminated plans for a control change and will resume trading on November 10 [39] - Poly Development reports a significant decrease in signed sales area and amount for October [40] - Wanhua Chemical's MDI phase II facility will undergo maintenance starting November 15 [41]